Drugs of unproven benefit for COVID-19: a pharma perspective on ethical allocation of available therapies

J Clin Invest. 2020 Nov 2;130(11):5622-5623. doi: 10.1172/JCI144186.

Authors

Arthur L Caplan^{1

2}, Joanne Waldstreicher³, Karla Childers³, Aran Maree⁴

Affiliations

¹ Division of Medical Ethics and.
² Department of Population Health, New York University, New York, New York, USA.
³ Johnson & Johnson, New Brunswick, New Jersey, USA.
⁴ Janssen Pharmaceutical Companies of Johnson & Johnson, New Brunswick, New Jersey, USA.

No abstract available

Publication types

Review

MeSH terms

Betacoronavirus*
Bioethical Issues*
COVID-19
Coronavirus Infections* / drug therapy
Coronavirus Infections* / epidemiology
Humans
Pandemics* / ethics
Pneumonia, Viral* / drug therapy
Pneumonia, Viral* / epidemiology
Resource Allocation / ethics*
SARS-CoV-2